For example, some companies indicated that a guideline was not adhered to in instances where modifications were anticipated and well justified e.g. It should be noted that there are some limitations to the data and that there is a possibility that companies may have misrepresented the status of implementation of a guideline in a region based on either a misunderstanding of the survey question or limited experience with the Agency. These differences were largely supported by justifications and specific examples, whereas gaps and divergences could be used to support training and capacity building efforts across agencies and companies. Responses, supported by evidence-based rationale, identified general agreement between agencies and companies, but with some divergences. E17.Ĭonclusion: Phase 2a of the study demonstrated that a comprehensive perception survey could be undertaken, where the response rate was excellent indicating strong interest in this initiative. In general, company perception and authority self-declaration were aligned or too early to assess based on limited experience e.g. adequately applying them in day-to-day practice.

Adherence to ICH Guidelines: Where implementation was confirmed, all the authorities felt that they were adhering to the Guidelines i.e.

Where there were modifications, all the authorities felt that these were objectively justified (=adequate implementation) and in general, company perception and authority self-declaration were aligned.

Adequacy of ICH Guideline implementation (based on modifications): In general, authorities declared that Guidelines were mostly implemented without modifications (=adequate implementation), though some Guidelines had more amendments e.g.

Company perception of implementation status was generally aligned with agency perception, but some differences were noted – e.g.

ICH Guideline implementation status: implementation of Guidelines based on self-declaration from the authorities was highest across Founding/Standing Regulatory Members, followed by Regulatory Members and Observers.Results: In general, there was strong evidence of adequate implementation and adherence to the Guidelines. The questionnaire was completed by companies (assessing all the participating authorities) and by authorities (assessing themselves only) in order to undertake a gap analysis. Method: An online questionnaire and definitions were developed by Centre for Innovation in Regulatory Science (CIRS) in collaboration with ICH and the ICH Implementation Subcommittee. The long-term objectives would be to establish a sustainable ICH-driven mechanism to assess Guidelines over time to inform ICH stakeholders on multiple areas as specified in the goals.

Objectives: The goal of this survey was to undertake a gap analysis by obtaining authorities’ and companies’ viewpoint on the implementation and adherence to the ICH Guidelines.

In the ICH Assembly Rules of Procedure, it is stated that there should be a process for the Assembly to monitor the progress of international harmonisation and coordinate efforts in this regard providing current state of play of the implementation and adherence to the ICH Guidelines.

Use (ICH) Articles of Association, the regulatory members of ICH are expected to implement ICH Guidelines. Background: According to the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human

Ich guidance